Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- The colonoscopy reimbursement math is not adding up (Becker’s Healthcare)
- Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey (Fierce Healthcare)
- Microbiome Testing Needs Its Standards Moment (Op-Med)
- Combined GI Endoscopy Has a Quality Assurance Gap. At Current Volume, That Gap Has Institutional Consequences. (HIT Consultant)
- Computer-aided polyp detection multicenter international randomized controlled study with a focus on community clinics: Gastroenterology Artificial INtelligence system for detecting colorectal polyps (ScienceDirect)
- Researchers Analyzing Colon Cancer Screenings Find Hope for Higher Retest Rates (Rutgers)
- Exclusive: Co-Founded By Former Whoop CTO, Throne Science Raises $10M To Track Gut Health From The Toilet (Crunchbase)
- GI Societies Oppose Proposed Federal Rule That Would Reshape Biomedical Research (American College of Gastroenterology)
